Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Diagnostics (Basel, Switzerland)
|
February 10, 2024
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research Database
Gemma Lepri, Cosimo Bruni, Lorenzo Tofani, et al.
Annals of the Rheumatic Diseases
|
October 23, 2025
Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome
Elpida Phithak, Fredrik N Albach, Ioanna Minopoulou, et al.
Rheumatology (Oxford, England)
|
January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Annals of the Rheumatic Diseases
|
August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study
Gabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
Annals of the Rheumatic Diseases
|
June 19, 2026
Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series
Fredrik N Albach, Elpida Phithak, Robert Biesen, et al.
Annals of the Rheumatic Diseases
|
January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)
Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.
Journal of the American Heart Association
|
February 26, 2025
Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
Andrea-Hermina Györfi, Tim Filla, Amin Polzin, et al.
RMD Open
|
November 3, 2022
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
Simon Kuster, Suzana Jordan, Muriel Elhai, et al.
Rheumatology (Oxford, England)
|
May 13, 2017
Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group
Veronika K Jaeger, Oliver Distler, Britta Maurer, et al.
Annals of the Rheumatic Diseases
|
April 11, 2019
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Muriel Elhai, Marouane Boubaya, Oliver Distler, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Diagnostics (Basel, Switzerland)
|
February 10, 2024
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research Database
Gemma Lepri, Cosimo Bruni, Lorenzo Tofani, et al.
Annals of the Rheumatic Diseases
|
October 23, 2025
Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome
Elpida Phithak, Fredrik N Albach, Ioanna Minopoulou, et al.
Rheumatology (Oxford, England)
|
January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Annals of the Rheumatic Diseases
|
August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study
Gabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
Annals of the Rheumatic Diseases
|
June 19, 2026
Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series
Fredrik N Albach, Elpida Phithak, Robert Biesen, et al.
Annals of the Rheumatic Diseases
|
January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)
Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.
Journal of the American Heart Association
|
February 26, 2025
Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
Andrea-Hermina Györfi, Tim Filla, Amin Polzin, et al.
RMD Open
|
November 3, 2022
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
Simon Kuster, Suzana Jordan, Muriel Elhai, et al.
Rheumatology (Oxford, England)
|
May 13, 2017
Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group
Veronika K Jaeger, Oliver Distler, Britta Maurer, et al.
Annals of the Rheumatic Diseases
|
April 11, 2019
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Muriel Elhai, Marouane Boubaya, Oliver Distler, et al.
Page
of 8